Hormonal
Four months of supervised endurance exercise training significantly reduces circulating leukocyte counts, particularly effector subtypes (CD4+ Teff, NK cells, neutrophils), in patients with metabolic syndrome.
If you have metabolic syndrome, engaging in supervised endurance exercise for 3-4 months can significantly lower your circulating immune cell counts, specifically those linked to inflammation (effector T cells, NK cells, neutrophils). This benefit occurs regardless of whether you choose moderate continuous training or high-intensity intervals, suggesting consistency and duration are key drivers for immune modulation.
Four months of ET reduced circulating leukocyte counts (63.5% of baseline, P = 8.0e-6), especially effector subtypes.
Why this rating
Retrospective analysis of two randomized clinical trials with n=58 total subjects; robust statistical significance (P=8.0e-6) but limited sample size.
Source
Cardiometabolic and immune response to exercise training in patients with metabolic syndrome: retrospective analysis of two randomized clinical trials
Katharina Lechner et al. · Frontiers in Cardiovascular Medicine · 2024
DOI 10.3389/fcvm.2024.1329633
More from this paper
- Improvements in cardiorespiratory fitness (VO2peak) do not consistently correlate with improvements in Metabolic Syndrome risk factors (blood pressure, lipids, glucose) following exercise training.Good
- Blood pressure reduction from exercise training in MetS patients is conditional on achieving a minimum cumulative exercise duration and lower baseline triglyceride levels.Good
- Neuropilin-1 (NRP-1) plasma levels are inversely associated with fasting plasma triglycerides, and changes in NRP-1 during exercise are inversely correlated with changes in triglycerides.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →